【摘要】 目的 :评价卡维地洛治疗充血性心力衰竭 (心衰 )的疗效和安全性。方法 :在本研究中以慢性心衰为研究对象 ,心衰标准用药为对照组 ;在此基础上加用卡维地洛为治疗组 ,用法由小剂量开始 ,逐渐递增。在 6个月的疗程中检查2次心脏彩色多普勒以评价左室功能。结果 :共入选 83例 ,研究结束时资料完整者 6 5例 (治疗组 33例、对照组 32例 ) ,两组的左室射血分数 (LVEF)均有增加 ,卡维地洛组由 ( 2 7 2± 2 8) %增至 ( 35 8± 2 5 ) % ,对照组由 ( 2 7 5± 1 9) %增至( 32 3± 2 7) % ,两组的LVEF增加有显著差异 (P <0 0 0 1)。本研究中 6例死亡 ,对照组占 5例。两组均无严重不良反应。结论 :卡维地洛在心衰标准用药基础上治疗充血性心力衰竭患者安全、有效。更多还原

【Abstract】 Objectives:To evaluate the effect and safety of carvedilol in treatment ofcongestive heart failure.Methods:In this study, Carvedilol group and control group were titrated from low does to target does in addition to standard therapy for patients with congestive heart failure. All patients were examined two times with Color Doppler Echocardiography during a six month period to assess LV function.Results:A total of 83 patients entered the study, and 65 patients have full data at study end point. Among of them, 33 were assigned to Carvedilol group and 32 to control group, LV ejection fraction(LVEF)increased in both groups, which are (27.2±2.8)% to(35.8±2.5)% in Carvedilol group and (27.5±1.9)% to(32.3± 2.7)% in control group at the end of the study. The increasing range of LVEF was more significant in Carvedilol group(8.6±3.9) % than incontrol group (4.8±3.4)%(P<0.001=.Five patients were dead in control group and one in Carvedilol group. The serious side effect was not found in both groups.Conclusions:This study demonstrates that Carvedilol is safe and effective in treatment of patients with congestive heart failure.更多还原